Health Care • Other Pharmaceuticals
$980.88 ▲ +20.32
(+2.12%)
MKT CAP: $114.36B • VOL: 721.5K
52W L $724 52W H $1,030
CONSENSUS RATING DISTRIBUTION (40 DESKS)
BUY: 30 HOLD: 8
SELL: 2
12M STREET TARGET RANGE
IMPLIED: +14.0%
LOW
$824
MEDIAN
$1,099
MEAN
$1,118
HIGH
$1,334
STREET BS CREDIBILITY SCORE 1Y BACKTESTED
68/100
EMPIRICAL HIT RATE VS SPOT
GRADES WHETHER SELL-SIDE TARGET REVISIONS LEAD OR CHASE MCK TAPE
MCK // FIRM-BY-FIRM ANALYST BACKTEST & BS DETECTOR (ANR <GO>)
CURRENT 90D STREET CONSENSUS
| INSTITUTION / ANALYST | ACTION | RATING | TARGET | PRIOR PT | CALL DATE | PX AT CALL | RET SINCE CALL | 1Y ACCURACY | BS GRADE |
|---|---|---|---|---|---|---|---|---|---|
| Morgan Stanley Institutional Equity Desk | REITERATE | OUTPERFORM | $1,186.86 | $1,128.01 | 2025-02-14 | $892.60 | +9.9% | 78% | A |
| Goldman Sachs Global Research Sector Coverage | TARGET REV | STRONG BUY | $1,235.91 | $1,157.44 | 2025-02-06 | $922.03 | +6.4% | 74% | A |
| J.P. Morgan Securities US Large Cap | REITERATE | BUY | $1,118.20 | $1,078.97 | 2025-01-29 | $941.64 | +4.2% | 67% | B |
| Bernstein Autonomous Forensic Coverage | INITIATE | HOLD | $1,000.50 | — | 2025-01-17 | $961.26 | +2.0% | 61% | B |
| Barclays Capital Americas Research | DOWNGRADE | UNDERPERFORM | $863.17 | $931.84 | 2025-01-09 | $872.98 | -11.2% | 42% | D |
| UBS Investment Bank Institutional Desk | UPGRADE | BUY | $1,167.25 | $1,020.12 | 2024-12-18 | $853.37 | +14.9% | 72% | A |
| Citigroup Global Markets Sector Lead | TARGET REV | HOLD | $951.45 | $990.69 | 2024-12-04 | $912.22 | -4.3% | 48% | C |